Application of prophylactic or pre-emptive therapy after allogeneic transplantation for high-risk patients with t(8;21) acute myeloid leukemia

References

• Prébet T, Boissel N, Reutenauer S, et al. Acute myeloid leukemia with translocation (8;21) or inversion (16) in elderly patients treated with conventional chemotherapy: a collaborative study of the French CBF-AML intergroup. J Clin Oncol. 2009;27(28):4747–53.
   PubMed Web of Science ®Google Scholar
• Döhner H, Wei AH, Appelbaum FR, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140(12):1345–77.
   PubMed Web of Science ®Google Scholar
• Beghini A. Core binding factor leukemia: chromatin remodeling moves towards oncogenic transcription. Cancers (Basel). 2019;11(12.
   PubMed Web of Science ®Google Scholar
• Kayser S, Kramer M, Martínez-Cuadrón D, et al. Characteristics and outcome of patients with core-binding factor acute myeloid leukemia and FLT3-ITD: results from an international collaborative study. Haematologica. 2022;107(4):836–43.
   PubMed Web of Science ®Google Scholar
• Zhu HH, Zhang XH, Qin YZ, et al. MRD-directed risk stratification treatment may improve outcomes of t(8;21) AML in the first complete remission: results from the AML05 multicenter trial. Blood. 2013;121(20):4056–62.
   PubMed Web of Science ®Google Scholar
• Guo WW, Liu X, Pang AM, et al. [Analysis of risk factors of relapse after allogeneic hematopoietic stem cell transplantation in patients with t (8;21) acute myeloid leukemia]. Zhonghua Xue Ye Xue Za Zhi. 2021;42(12):998–1004.
   PubMedGoogle Scholar
• Qin Y-Z, Wang Y, Xu L-P, et al. The dynamics of RUNX1-RUNX1T1 transcript levels after allogeneic hematopoietic stem cell transplantation predict relapse in patients with t(8;21) acute myeloid leukemia. J Hematol Oncol. 2017;10(1):44.
   PubMedGoogle Scholar
• Wang Y, Wu DP, Liu QF, et al. In adults with t(8;21)AML, posttransplant RUNX1/RUNX1T1-based MRD monitoring, rather than c-KIT mutations, allows further risk stratification. Blood. 2014;124(12):1880–6.
   PubMed Web of Science ®Google Scholar
• Qin YZ, Wang Y, Xu LP, et al. The dynamics of RUNX1-RUNX1T1 transcript levels after allogeneic hematopoietic stem cell transplantation predict relapse in patients with t(8;21) acute myeloid leukemia. J Hematol Oncol. 2017;10(1):44.
   PubMedGoogle Scholar
• Konuma T, Kondo T, Masuko M, et al. Prognostic value of measurable residual disease at allogeneic transplantation for adults with core binding factor acute myeloid leukemia in complete remission. Bone Marrow Transplant. 2021;56(11):2779–87.
   PubMed Web of Science ®Google Scholar
• Yalniz FF, Patel KP, Bashir Q, et al. Significance of minimal residual disease monitoring by real-time quantitative polymerase chain reaction in core binding factor acute myeloid leukemia for transplantation outcomes. Cancer. 2020;126(10):2183–92.
   PubMed Web of Science ®Google Scholar
• Xuan L, Liu Q. Maintenance therapy in acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation. J Hematol Oncol. 2021;14(1):4.
   PubMed Web of Science ®Google Scholar
• Lee CJ, Savani BN, Mohty M, et al. Post-remission strategies for the prevention of relapse following allogeneic hematopoietic cell transplantation for high-risk acute myeloid leukemia: expert review from the acute leukemia working party of the European society for blood and marrow transplantation. Bone Marrow Transplant. 2019;54(4):519–30.
   PubMed Web of Science ®Google Scholar
• Wang Y, Liu QF, Wu DP, et al. Impact of prophylactic/preemptive donor lymphocyte infusion and intensified conditioning for relapsed/refractory leukemia: a real-world study. Sci China Life Sci. 2020;63(10):1552–64.
   PubMed Web of Science ®Google Scholar
• Fan S, Shen MZ, Zhang XH, et al. Preemptive immunotherapy for minimal residual disease in patients With t(8;21) acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation. Front Oncol. 2021;11(773394.
   Google Scholar
• Platzbecker U, Wermke M, Radke J, et al. Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial. Leukemia. 2012;26(3):381–9.
   PubMed Web of Science ®Google Scholar
• Platzbecker U, Middeke JM, Sockel K, et al. Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial. Lancet Oncol. 2018;19(12):1668–79.
   PubMed Web of Science ®Google Scholar
• Lin L, Que Y, Lu P, et al. Chidamide inhibits acute myeloid leukemia cell proliferation by lncRNA VPS9D1-AS1 downregulation via MEK/ERK signaling pathway. Front Pharmacol. 2020;11:569651.
   PubMed Web of Science ®Google Scholar
• Li Z, Zhang J, Zhou M, et al. Epigenetic therapy with chidamide alone or combined with 5-azacitidine exerts antitumour effects on acute myeloid leukaemia cells in vitro. Oncol Rep. 2022;47:4.
   PubMed Web of Science ®Google Scholar
• Yan CH, Liu DH, Liu KY, et al. Risk stratification-directed donor lymphocyte infusion could reduce relapse of standard-risk acute leukemia patients after allogeneic hematopoietic stem cell transplantation. Blood. 2012;119(14):3256–62.
   PubMed Web of Science ®Google Scholar
• Willekens C, Blanchet O, Renneville A, et al. Prospective long-term minimal residual disease monitoring using RQ-PCR in RUNX1-RUNX1T1-positive acute myeloid leukemia: results of the French CBF-2006 trial. Haematologica. 2016;101(3):328–35.
   PubMed Web of Science ®Google Scholar
• Halaburda K, Labopin M, Mailhol A, et al. Allogeneic stem cell transplantation in second complete remission for core binding factor acute myeloid leukemia: a study from the acute leukemia working party of the European society for blood and marrow transplantation. Haematologica. 2020;105(6):1723–30.
   PubMed Web of Science ®Google Scholar
• Oran B, de Lima M, Garcia-Manero G, et al. A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patients. Blood Adv. 2020;4(21):5580–8.
   PubMed Web of Science ®Google Scholar
• Tang Y, Zhou Z, Yan H, et al. Case report: preemptive treatment With Low-dose PD-1 blockade and azacitidine for molecular relapsed acute myeloid leukemia With RUNX1-RUNX1T1 after allogeneic hematopoietic stem cell transplantation. Front Immunol. 2022;13:810284.
   PubMedGoogle Scholar